Covid-19 vaccines: A result of the ‘Idea Multiplier’

11-17-2020
Covid-19 vaccines: A result of the ‘Idea Multiplier’

More to come in genetics and biomedicine

 

The Covid-19 pandemic has been breathtaking in its ability to unleash profound effects on nearly everyone in the world. Equally breathtaking are the biomedical advances that have enabled 47 vaccine candidates to reach clinical evaluation in recent months.1

News on Monday, November 9, that one of those vaccine candidates appears to protect a vast majority from Covid-19 is raising the confidence of investors and public health experts alike. Vanguard earnestly hopes that further study confirms the good news and that a vaccine can be approved in the months ahead for broad use. It’s conceivable that more of the vaccine candidates can report similar efficacy in the weeks ahead.

We’re not surprised that this point was reached so quickly. The fields of genetics and biomedicine have been rife with innovative ideas in the last decade, and successes seem poised to have a cascading effect on productivity in the decade ahead. It’s a phenomenon we identified in The Idea Multiplier, our 2019 research that found that future productivity is fundamentally driven by the generation, dissemination, and further expansion of ideas.

Idea sharing: A significant force for productivity growth

Our research introduced what we termed the “Idea Multiplier,” a quantifying over time of academic-paper citations within and across industries and countries based on nearly two billion records. We found that idea-sharing is a significant force for future productivity growth, and that a recent low-growth era was nearing an end.

The accompanying graph shows how the Idea Multiplier as it’s related to genetics and biomedicine has recently accelerated at a pace similar to that of computers and telecommunications nearly four decades ago.

We won’t let our optimism about vaccine developments cause us to lose sight of the immense challenges ahead. The spread of Covid-19 is accelerating, too, with more than 50 million cases reported globally to date and more than 100,000 new daily infection cases in some countries, including the United States, recently.2 Production and distribution of a vaccine will take time.

Economies have recovered somewhat from the sharp falls they had suffered since the onset of the pandemic, but even a highly effective vaccine won’t lead to stronger economic growth overnight. Nevertheless, this crisis will eventually end, and this week brought a tangible signal of that, one we know was a decade of idea-sharing in the making.

1. Source: World Health Organization, November 3, 2020.
2. Source: Johns Hopkins Coronavirus Resource Center, November 9, 2020.

Joseph H. Davis, PhD, is a Vanguard principal and the global head of The Vanguard Group, Inc.’s Investment Strategy Group, whose research and client-facing team develops asset allocation strategies and conducts research on the capital markets, the global economy, portfolio construction and related investment topics. As Vanguard’s global chief economist, Mr. Davis is also a key member of the senior portfolio management team for Vanguard Fixed Income Group, which oversees more than US$700 billion in assets under management.

Important Notes/Disclosures

© 2020 by Vanguard Group. All rights reserved. Reproduction in whole or in part by any means without prior written permission is prohibited. This article first appeared on the “Insights“ page of the Vanguard Group, Inc.’s website. Used with permission.

All investing is subject to risk, including the possible loss of the money you invest. The views expressed in this material are based on the author's assessment as of the first publication date (November 2020), are subject to change without notice and may not represent the views and/or opinions of Vanguard Investments Canada Inc. The author may not necessarily update or supplement their views and opinions whether as a result of new information, changing circumstances, future events or otherwise.

Any "forward-looking" information contained in this material should be construed as general investment or market information and no representation is being made that any investor will, or is likely to achieve, returns similar to those mentioned in this material or anticipated in this material.

This material is for informational purposes only. This material is not intended to be relied upon as research, investment, or tax advice and is not an implied or express recommendation, offer or solicitation to buy or sell any security or to adopt any particular investment or portfolio strategy. Any views and opinions expressed do not take into account the particular investment objectives, needs, restrictions and circumstances of a specific investor and, thus, should not be used as the basis of any specific investment recommendation.

Please consult your financial and/or tax advisor for financial and/or tax information applicable to your specific situation.

In this material, references to "Vanguard" are provided for convenience only and may refer to, where applicable, only The Vanguard Group, Inc., and/or may include its affiliates, including Vanguard Investments Canada Inc.